Literature DB >> 11750214

Patient- and provider-reported adherence: toward a clinically useful approach to measuring antiretroviral adherence.

J H Wagner1, A C Justice, M Chesney, G Sinclair, S Weissman, M Rodriguez-Barradas.   

Abstract

We seek to develop a clinically useful measure of antiretroviral medication adherence. Because there is no gold standard for adherence, we will assess the clinical validity of patient- and provider-reported adherence by the strength of their expected associations with current viral load, depressive symptoms, alcohol and illicit drug use, and homelessness. The Veterans Aging Cohort 3 Site Study (VACS 3) is a multisite study of 881 patients at Cleveland, Houston, and Manhattan Veterans Affairs health care systems. Data was collected on adherence using patient report and provider assessment; depressive symptoms using the Center for Epidemiological Studies Depression (CESD) and provider assessment; alcohol use using the Alcohol Use Disorders Identification Test (AUDIT) and provider assessment; and homelessness using patient report only. Viral load was collected from electronic laboratory data. Although agreement between providers and patients about the patient's adherence was not better than chance (61%; weighted kappa =.07), both patient and provider-reported adherence were related to viral load (P <.001), current alcohol use (P <.01), current drug use (P <.01), and depressive symptoms (P <.001). Patient-reported adherence was also associated with homelessness (P <.05). In multivariate regression models, provider assessment of adherence demonstrated independent associations with viral load (P <.001), current alcohol use (P <.001), current drug use (P <.001), and depressive symptoms (P <.001) after adjustment for the patient's report of adherence (also significantly associated). The consistent and largely independent association between patient and provider reported adherence and a range of variables previously shown to be associated with adherence suggests that patient- and provider-reported adherence independently measure actual adherence. Future work will explore how patient- and provider-reported adherence might best be combined, and whether the measure may be further enhanced with pharmacy refill data.

Entities:  

Mesh:

Year:  2001        PMID: 11750214     DOI: 10.1016/s0895-4356(01)00450-4

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  49 in total

1.  Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons.

Authors:  Andy I Choi; Eric Vittinghoff; Steven G Deeks; Cristin C Weekley; Yongmei Li; Michael G Shlipak
Journal:  AIDS       Date:  2011-06-19       Impact factor: 4.177

2.  Controlling anal incontinence in women by performing anal exercises with biofeedback or loperamide (CAPABLe) trial: Design and methods.

Authors:  J Eric Jelovsek; Alayne D Markland; William E Whitehead; Matthew D Barber; Diane K Newman; Rebecca G Rogers; Keisha Dyer; Anthony Visco; Vivian W Sung; Gary Sutkin; Susan F Meikle; Marie G Gantz
Journal:  Contemp Clin Trials       Date:  2015-08-18       Impact factor: 2.226

Review 3.  Measuring adherence to highly active antiretroviral therapy: implications for research and practice.

Authors:  Thomas Kerr; John Walsh; Elisa Lloyd-Smith; Evan Wood
Journal:  Curr HIV/AIDS Rep       Date:  2005-11       Impact factor: 5.071

Review 4.  Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management.

Authors:  Jane M Simoni; Ann E Kurth; Cynthia R Pearson; David W Pantalone; Joseph O Merrill; Pamela A Frick
Journal:  AIDS Behav       Date:  2006-05

Review 5.  Practical and conceptual challenges in measuring antiretroviral adherence.

Authors:  Karina M Berg; Julia H Arnsten
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-01       Impact factor: 3.731

6.  Association of tenofovir exposure with kidney disease risk in HIV infection.

Authors:  Rebecca Scherzer; Michelle Estrella; Yongmei Li; Andy I Choi; Steven G Deeks; Carl Grunfeld; Michael G Shlipak
Journal:  AIDS       Date:  2012-04-24       Impact factor: 4.177

7.  Health status, health care use, medication use, and medication adherence among homeless and housed people living with HIV/AIDS.

Authors:  Daniel P Kidder; Richard J Wolitski; Michael L Campsmith; Glenn V Nakamura
Journal:  Am J Public Health       Date:  2007-10-30       Impact factor: 9.308

Review 8.  Health Technology-Enabled Interventions for Adherence Support and Retention in Care Among US HIV-Infected Adolescents and Young Adults: An Integrative Review.

Authors:  Ann-Margaret Dunn Navarra; Marya Viorst Gwadz; Robin Whittemore; Suzanne R Bakken; Charles M Cleland; Winslow Burleson; Susan Kaplan Jacobs; Gail D'Eramo Melkus
Journal:  AIDS Behav       Date:  2017-11

9.  Defining an evidence-based cutpoint for medication adherence in heart failure.

Authors:  Jia-Rong Wu; Debra K Moser; Marla J De Jong; Mary Kay Rayens; Misook L Chung; Barbara Riegel; Terry A Lennie
Journal:  Am Heart J       Date:  2008-12-24       Impact factor: 4.749

10.  Individual patients hold different beliefs to prescription medications to which they persist vs nonpersist and persist vs nonfulfill.

Authors:  Colleen A McHorney; Abhijit S Gadkari
Journal:  Patient Prefer Adherence       Date:  2010-07-21       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.